A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti- Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers | Zendy

Melicent C. Peck | Zendy; Michael E. Rothenberg | Zendy; Rong Deng | Zendy; Nicholas LewinKoh | Zendy; Gaohong She | Zendy; Amrita V. Kamath | Zendy; Montserrat CarrascoTriguero | Zendy; Ola M. Saad | Zendy; Aide Castro | Zendy; Lisa U. Teufel | Zendy; Daniel Dickerson | Zendy; Marisa Leonardelli | Zendy; Jorge A. Tavel | Zendy

Open Access

A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti- Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers

Author(s) -

Melicent C. Peck,

Michael E. Rothenberg,

Rong Deng,

Nicholas LewinKoh,

Gaohong She,

Amrita V. Kamath,

Montserrat CarrascoTriguero,

Ola M. Saad,

Aide Castro,

Lisa U. Teufel,

Daniel Dickerson,

Marisa Leonardelli,

Jorge A. Tavel

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02588-18

Subject(s) - antibiotics , staphylococcus aureus , tolerability , medicine , pharmacokinetics , conjugate , antibody , microbiology and biotechnology , pharmacology , immunology , adverse effect , biology , bacteria , mathematical analysis , genetics , mathematics

Staphylococcus aureus causes serious bacterial infections with high morbidity and mortality, necessitating the discovery of new antibiotics. DSTA4637S is a novel antibody-antibiotic conjugate designed to target intracellularS. aureus that is not adequately eliminated by current standard-of-care antibiotics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research